Auxilium generic Testim strategy defended at UBS UBS believes Auxilium shares are lower as investors assume Upsher’s generic version of Testim could be approved as an AB-rated generic, but the firm noted that is not yet the case. UBS thinks Auxilium shares will recover as investors recognize that the generic strategy should maximize Testim sales over the medium term and maintains its Buy rating and $31 price target on the stock.
Endo upgraded to Overweight from Neutral at Piper Jaffray Piper Jaffray upgraded Endo (ENDP) to Overweight with an $84 price target citing an improved asset base following the takeover of Auxilium (AUXL).
Auxilium downgraded to Neutral from Buy at Mizuho Mizuho downgraded Auxilium (AUXL) to Neutral following the company's agreement to be acquired by Endo (ENDP). The firm expects shareholders to approve the deal and does not expect a competing bid.